Amivantamab: A Novel Advance in the Treatment of Non-small Cell Lung Cancer

Amivantamab is a fully human bispecific monoclonal antibody indicated for treating patients with specifically large cell lung cancer. Its dosage is based on the patient's initial body weight and is administered via intravenous infusion after dilution. Therefore, this drug is given as a strategy...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-05, Vol.16 (5), p.e60851
Main Authors: Zavaleta-Monestel, Esteban, García-Montero, Jonathan, Arguedas-Chacón, Sebastián, Quesada-Villaseñor, Ricardo, Barrantes-López, Monserrat, Arroyo-Solís, Rebeca, Zuñiga-Orlich, Carlos E
Format: Article
Language:English
Subjects:
Brand names
Cancer therapies
Chemotherapy
Colorectal cancer
DNA repair
Epidermal growth factor
FDA approval
Internal Medicine
Kinases
Ligands
Lung cancer
Medical prognosis
Metastasis
Monoclonal antibodies
Mutation
Patients
Pulmonology
Targeted cancer therapy
Therapeutics
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amivantamab is a fully human bispecific monoclonal antibody indicated for treating patients with specifically large cell lung cancer. Its dosage is based on the patient's initial body weight and is administered via intravenous infusion after dilution. Therefore, this drug is given as a strategy due to the great need for a molecule targeting epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition factor (MET), as acquired resistance to tyrosine kinase inhibitors (TKIs) was observed in the treatment of large cell lung cancer. This article encompasses a review of the benefits of amivantamab for patients with non-small cell lung cancer (NSCLC). This drug is the first therapy directed against this specific mutation, and unlike others, it could bind to two genetic receptors, whereas antibodies, in general, are directed toward a single receptor.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.60851